CENTOGENE Launches NEW CentoXome® - An Enhanced Whole Exome Sequencing Solution

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 1, 2020 (GLOBE NEWSWIRE)

  • World leader and trusted partner in rare diseases releases enhanced Whole Exome Sequencing (WES) solution to improve diagnosis in complex and unsolved patient cases
  • NEW CentoXome® provides best-in-class clinical insights based on CENTOGENE’s unique rare disease-centric Bio/Databank, enabling more rapid diagnosis and identification of treatment options
  • Superior technology with excellent clinical coverage and diagnostic power in a single test increases diagnostic yield by up to 20% compared to routine WES
  • Life-long support with free-of-charge and proactive variant reclassification demonstrates unique commitment to improving the lives of patients with rare diseases

Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced the launch of NEW CentoXome, an enhanced next-generation sequencing-based assay.

As world leader and trusted partner in rare diseases, CENTOGENE has been at the forefront of providing diagnostic solutions for over 15 years. Coupling insights from the Company’s unique rare disease-centric Bio/Databank with superior omics technology, patients and their physicians will benefit from a unique approach that increases diagnostic yield by up to 20% compared to conventional WES via enhanced coverage of the exome, full mitochondrial genome, and known medically-associated genes and variants.

“Since 2006, we have helped over half a million patients, authored more than 200 peer-reviewed publications, and performed tens of thousands of Whole Exome Sequencing tests. Building on this expertise, we believe that this enhanced service will enable physicians around the world to deliver the most rapid and reliable diagnosis and accelerate access to treatment options,” said Dr. Maximilian Schmid, CENTOGENE’s Chief Commercial Officer, Diagnostics.

NEW CentoXome - Superior Technology With Unmatched Clinical Coverage in a Single Test

The enhanced WES solution consists of three seamlessly integrated key updates:

More Insights

Improved clinical reporting based on bioinformatics, artificial intelligence (AI), and medical expert-based analysis of CENTOGENE’s unique Bio/Databank of  approximately 600,000 patients from more than 120 countries and over 31 million unique variants

Enhanced Coverage

  • Innovative technology with uniform coverage across the entire exome (approximately 20,000 genes), full mitochondrial genome, and known medically-associated genes and variants

Increased Diagnostic Yield

  • By boosting clinically relevant regions and providing panel-grade quality coverage of approximately 8,000 medically-associated genes, diagnostic yield increases by up to 20% compared to routine WES

Demonstrating CENTOGENE’s unique commitment to improving the lives of patients with rare diseases, NEW CentoXome is paired with life-long diagnostic support and a free-of-charge and proactive reclassification program.

Further information about NEW CentoXome


CENTOGENE engages in diagnosis and research around rare diseases transforming real-world clinical, genetic, and multiomic data to diagnose, understand, and treat rare diseases. Our goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our extensive rare disease knowledge and data. CENTOGENE has developed a global proprietary rare disease platform based on our real-world data repository with over 3.9 billion weighted data points from approximately 600,000 patients representing over 120 different countries as of December 31, 2020.

The Company’s platform includes epidemiologic, phenotypic, and genetic data that reflects a global population, as well as a biobank of patients’ blood samples and cell cultures. CENTOGENE believes this represents the only platform focused on comprehensive analysis of multi-level data to improve the understanding of rare hereditary diseases. It allows for better identification and stratification of patients and their underlying diseases to enable and accelerate discovery, development, and access to orphan drugs. As of December 31, 2020, the Company collaborated with over 30 pharmaceutical partners.

Important Notice and Disclaimer

This press release contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company’s opinions, expectations, beliefs, plans, objectives, assumptions, or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of our strategies, financing plans, growth opportunities, and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project” or “expect,” “may,” “will,” “would,” “could,” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the Company. However, these forward- looking statements are not a guarantee of our performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties, and other variable circumstances, such as negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, the effects of the COVID-19 pandemic on our business and results of operations, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration partners, including our ability to manage growth and enter into new client relationships, our dependency on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of exchange rates, or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the Company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The Company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

For further information, please refer to the Risk Factors section in our Annual Report for the year ended December 31, 2020, on Form 20-F filed with the SEC on April 15, 2021, and other reports and documents furnished to or filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website.

Media Contact:

Ben Legg
Corporate Communications

FTI Consulting
Bridie Lawlor O’Boyle